Analyst firms · Barclays · COR
Barclays COR price target and rating history
Cencora Inc. (COR) · Health Care
Barclays rates Cencora Inc. (COR) Overweight with a $400 price target, as of its latest action on Dec 9, 2025. It has published 5 rating actions on COR since August 2021, including 1 upgrade and 0 downgrades. Across 4 firms with a COR price target in the last 12 months, the median target is $400. Barclays's target matches it.
- Current rating
- Overweight
- Price target
- $400
- Median target, all firms
- $400
- Actions on COR
- 5
Barclays price target on COR
Every Barclays rating on COR
- Dec 9, 2025
- Jan 3, 2024
- Nov 16, 2021
- Oct 29, 2021
- Aug 25, 2021
How other firms rate COR
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| RBC Capital Markets | Sector Perform | $330 | Aug 19, 2026 |
| William Blair | Mkt Perform | Apr 28, 2026 | |
| Morgan Stanley | Overweight | $400 | Jan 29, 2026 |
| Jefferies | Buy | $440 | Jan 22, 2026 |
| Barclays | Overweight | $400 | Dec 9, 2025 |
Questions about Barclays and COR
- What is Barclays's price target for COR?
- Barclays's latest stated price target for Cencora Inc. (COR) is $400, from its action on Dec 9, 2025.
- What is Barclays's rating on COR?
- Barclays rates COR Overweight, a bullish rating, as of Dec 9, 2025.
- When did Barclays last change its view on COR?
- On Dec 9, 2025, Barclays starts coverage at Overweight, price target $400.
- How does Barclays's COR target compare with other analysts?
- Across 4 firms with a COR price target in the last 12 months, the median target is $400. Barclays's target matches it.
More COR rating histories
All Barclays ratingsCOR news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.